Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ASSIGNMENT OF SUBLEASE AND SUB-SUBLEASEAssignment of Sublease and Sub-Sublease • February 12th, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This ASSIGNMENT OF SUBLEASE AND SUB-SUBLEASE (this “Assignment”) is made as of December 13, 2019 by and between Casebia Therapeutics LLC (“Assignor”) and CRISPR Therapeutics, Inc. (“Assignee”).
OPTION AGREEMENT BETWEENOption Agreement • February 12th, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York
This OPTION AGREEMENT (this “Agreement”) is entered into as of December 13, 2019 (the “Effective Date”) by and between Bayer Healthcare LLC (“Bayer”) and CRISPR Therapeutics AG (“CRISPR”). Bayer and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.”
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.Retirement Agreement • February 12th, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York
This Retirement Agreement (this “Agreement”) is made and entered into as of December 13, 2019, by and among Casebia Therapeutics Limited Liability Partnership, a limited liability partnership incorporated in England and Wales (“Casebia”), Bayer HealthCare LLC, a limited liability company formed in Delaware (“Bayer”), CRISPR Therapeutics AG, a stock corporation organized under the laws of Switzerland (“CRISPR AG”), and CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“CRISPR Inc., and together with CRISPR AG, “CRISPR”).
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.Joint Venture Termination Agreement • February 12th, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York
This Joint Venture Termination Agreement (this “Agreement”) is made and entered into as of December 13, 2019, by and among Bayer HealthCare LLC, a limited liability company formed in Delaware (“Bayer” for purposes of this Agreement, other than Article II), Bayer AG, a German stock corporation (Aktiengesellschaft) (only for purposes of Article II, as applicable), Bayer Pharma AG, a German stock corporation (only for purposes of Article II, as applicable), CRISPR Therapeutics AG, a stock corporation organized under the laws of Switzerland (“CRISPR AG” or “CRISPR” (for purposes of this Agreement, other than Article II)), CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”) (only for purposes of Article II, as applicable), CRISPR Therapeutics Limited, a corporation organized under the laws of England and Wales (“CRISPR UK”) (only for purposes of Article II, as applicable) and TRACR Hematology Ltd., a UK limited company (“TRACR”) (only f
Amendment No. 2 to the Research Collaboration Agreement of September 17, 2018 by and between ViaCyte, Inc. and CRISPR Therapeutics AGResearch Collaboration Agreement • February 12th, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This Amendment No. 2 (“Second Amendment”) to the Research Collaboration Agreement dated September 17, 2018 (the “Agreement”), as amended by Amendment No. 1 dated April 30, 2019 (“First Amendment”), by and between ViaCyte, Inc. (“ViaCyte”) and CRISPR Therapeutics AG (“CRISPR”) is effective as of October 21, 2019 (the “Second Amendment Effective Date”).
Amendment No. 1 to the Research Collaboration Agreement of September 17, 2018 by and between ViaCyte, Inc. and CRISPR Therapeutics AGResearch Collaboration Agreement • February 12th, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This Amendment No. 1 (the “Amendment”) to the Research Collaboration Agreement (the “Agreement”) of September 17, 2018 by and between ViaCyte, Inc. (“ViaCyte”) and CRISPR Therapeutics AG (“CRISPR”) is effective as of April 30, 2019 (the “Amendment Effective Date”).
